Special Issue "Advances and Novel Treatment Options in Metastatic Melanoma"
Deadline for manuscript submissions: closed (30 August 2020).
Interests: melanoma markers; angiogenic factors; melanoma therapy and diagnosis; autophagy
Interests: melanoma; bcl-2; microenvironment; angiogenesis
The field of cancer treatments is experiencing a revolutionary age, with the continuous release of new effective drugs gradually changing the prognosis of several cancer types. This is true in the melanoma field as well. An unprecedented scenario is likely opening regarding melanoma treatment, where effective approaches, such as different drug or different strategy combinations may be available in a relatively short time.
An open view at the options available, at the different new research-lines going on, and at the bottlenecks is needed.
In the present Special Issue, manuscripts reporting original data or updated literature reviews in the melanoma field are sought. Manuscripts should focus on the known new effective molecular approaches or on the possible new molecular targets, strong candidates for future prognostic/therapeutic strategies. The molecular basis of the novel toxic/side effects and possible drawbacks related to the new drugs currently under clinical use are also a hot topic that will be addressed in the Special Issue. In addition, solid-based nutrition interventions and new acquisitions on microbiome-related melanoma studies are sought, as well as studies regarding how to improve quality of life in metastatic melanoma patients.
Manuscripts reporting at least one cartoon to be used as a visual-abstract are encouraged.
Prof. Dr. Antonio Facchiano
Dr. Donatella Del Bufalo
Dr. Alessandra Carè
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- new drugs
- nutrition-based approaches
- toxic effects
- drug combination
- strategy combination
- quality of life